Apimeds Pharmaceuticals US, Inc. acquires MindWave (2026)

Deal facts

Buyer: Apimeds Pharmaceuticals US, Inc.
Target: MindWave
Deal value: Not disclosed
Announced: 17 February 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: Not stated

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

30 Sept 2025CompletedClosed
Apimeds Pharmaceuticals US, Inc. completes acquisition of MindWave
Item 9.01 of Form 8-K in connection with the reverse merger transaction previously reported under Item 2.01 (Completion of Acquisition or Disposition of Assets) in the Original Report. This Amendment does not reflect any events occurring after the filing of the Original Report and does not amend or update any disclosures contained therein, except as expressly provided herein. 1 Item 2.01 Completio
Source

OpinionExit Mode editorial

We see a clear signal in the completion of the merger between Apimeds Pharmaceuticals US, Inc and MindWave. Both entities operate within the US healthcare sector, and the structure is defined as a merger of equals. This is not a standard acquisition where one party absorbs the other. Instead, the deal implies a strategic consolidation of capabilities, likely aimed at creating a more resilient entity capable of navigating the complex regulatory landscape of the American pharmaceutical market. The announcement date of 17 February 2026 marks the formal recognition of this new combined strength.

For the SME founder reading this, the choice of a merger of equals structure carries distinct implications for control and governance. Unlike a traditional sale where the buyer dictates terms, this model requires a high degree of alignment between the two founding teams regarding culture, strategy, and operational integration. The absence of a disclosed value in the public record is typical for such transactions, often relying on share swaps rather than cash consideration. This mechanism shifts the focus from a one-off exit to a long-term partnership where both parties share the risks and rewards of the combined entity. It demands that founders remain deeply engaged post-completion rather than stepping back.

The regulatory context for any US healthcare merger of this nature invariably involves scrutiny from the Federal Trade Commission or the Department of Justice to ensure competition is not stifled. While the deal is already marked as completed, the path to this point would have required rigorous due diligence on intellectual property portfolios and pipeline assets. The success of this integration now hinges on the ability to merge distinct R&D workflows without losing the agility that characterised both original companies. We believe this structure offers a viable path for founders who wish to scale without surrendering their strategic vision to a larger corporate parent.

You should review your current shareholder agreement to identify change-of-control covenants that might trigger if you ever pursue a similar merger of equals. Ensure your board has the authority to negotiate governance structures that protect your operational autonomy during the integration phase, as this is where most such deals face friction.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More merger of equals deals More from Apimeds Pharmaceuticals US, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC to acquire Selectis Health, Inc.

GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC and Selectis Health, Inc. entered the Exit Mode archive.

Buyer: GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC
Target: Selectis Health, Inc.
Deal value: USD 15,700,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

4 May 2026Firm intentionHealthcare

Aura Biosciences, Inc. to acquire Matrix Capital Management Master Fund, LP

Aura Biosciences, Inc. and Matrix Capital Management Master Fund, LP entered the Exit Mode archive.

Buyer: Aura Biosciences, Inc.
Target: Matrix Capital Management Master Fund, LP
Deal value: Not disclosed
Deal type: share buyback

Read deal Healthcare deals share buyback deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

Buyer history